Cell differential, cytogenetic results, and outcomes for patients with acute erythroleukemia
| Patient no. . | Age, sex . | Blasts, % of total . | Erythroid precursors, % . | Blasts, % of NEC . | Cytogenetics . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 61, M | 4.0 | 83.6 | 24.0 | Abnormal* | Alive 3 months after diagnosis, no therapy |
| 2 | 44, M | 7.0 | 75.4 | 28.4 | Normal male | Relapsed |
| 3 | 60, M | 7.4 | 67.2 | 22.6 | Abnormal† | Died of disease 2 months after diagnosis, standard chemotherapy |
| 4 | 23, M | 11.6 | 58.2 | 27.0 | Normal male | Clinical remission, S/P ALLO-BMT‡ |
| 5 | 81, F | 7.0 | 75.0 | 28.0 | Normal female | Lost to follow-up |
| Patient no. . | Age, sex . | Blasts, % of total . | Erythroid precursors, % . | Blasts, % of NEC . | Cytogenetics . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 61, M | 4.0 | 83.6 | 24.0 | Abnormal* | Alive 3 months after diagnosis, no therapy |
| 2 | 44, M | 7.0 | 75.4 | 28.4 | Normal male | Relapsed |
| 3 | 60, M | 7.4 | 67.2 | 22.6 | Abnormal† | Died of disease 2 months after diagnosis, standard chemotherapy |
| 4 | 23, M | 11.6 | 58.2 | 27.0 | Normal male | Clinical remission, S/P ALLO-BMT‡ |
| 5 | 81, F | 7.0 | 75.0 | 28.0 | Normal female | Lost to follow-up |
M indicates male; and F, female.
Abnormal karyotype included 45-46, XY, −5, −7, add (8)(p21)[2], −15[1], add(17)(p11.2), −21[1], +mar [13].
Abnormal karyotype included 41-45, X, −Y, del(5)(q13q33), −16, add(21)(q22), dic(17;20)(p13;q11.2)+20, add(20)(q11.2).
Status after allogeneic bone marrow transplantation.